Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Identifieur interne : 000506 ( Main/Exploration ); précédent : 000505; suivant : 000507Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Auteurs : Balamurugan Shanmugaraj [Thaïlande] ; Konlavat Siriwattananon [Thaïlande] ; Kittikhun Wangkanont [Thaïlande] ; Waranyoo Phoolcharoen [Thaïlande]Source :
- Asian Pacific journal of allergy and immunology [ 0125-877X ] ; 2020.
Descripteurs français
- KwdFr :
- Anticorps antiviraux (usage thérapeutique), Anticorps monoclonaux (usage thérapeutique), Anticorps neutralisants (usage thérapeutique), Chine, Coronavirus du syndrome respiratoire du Moyen-Orient, Glycoprotéine de spicule des coronavirus (), Humains, Immunothérapie, Infections à coronavirus (), Pneumopathie virale (), Récepteurs viraux (), Sites de fixation, Structure tertiaire des protéines, Virus du SRAS.
- MESH :
- usage thérapeutique : Anticorps antiviraux, Anticorps monoclonaux, Anticorps neutralisants.
- Chine, Coronavirus du syndrome respiratoire du Moyen-Orient, Glycoprotéine de spicule des coronavirus, Humains, Immunothérapie, Infections à coronavirus, Pneumopathie virale, Récepteurs viraux, Sites de fixation, Structure tertiaire des protéines, Virus du SRAS.
- Wicri :
- geographic : République populaire de Chine.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (therapeutic use), Antibodies, Neutralizing (therapeutic use), Antibodies, Viral (therapeutic use), Betacoronavirus, Binding Sites, China, Coronavirus Infections (therapy), Humans, Immunotherapy, Middle East Respiratory Syndrome Coronavirus, Pneumonia, Viral (therapy), Protein Structure, Tertiary, Receptors, Virus (chemistry), SARS Virus, Spike Glycoprotein, Coronavirus (chemistry).
- MESH :
- chemical , chemistry : Receptors, Virus, Spike Glycoprotein, Coronavirus.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Neutralizing, Antibodies, Viral.
- geographic : China.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Binding Sites, Humans, Immunotherapy, Middle East Respiratory Syndrome Coronavirus, Protein Structure, Tertiary, SARS Virus.
Abstract
Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen.
DOI: 10.12932/AP-200220-0773
PubMed: 32134278
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000807
- to stream PubMed, to step Curation: 000807
- to stream PubMed, to step Checkpoint: 000467
- to stream Ncbi, to step Merge: 000D72
- to stream Ncbi, to step Curation: 000D72
- to stream Ncbi, to step Checkpoint: 000D72
- to stream Main, to step Merge: 000508
- to stream Main, to step Curation: 000506
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).</title><author><name sortKey="Shanmugaraj, Balamurugan" sort="Shanmugaraj, Balamurugan" uniqKey="Shanmugaraj B" first="Balamurugan" last="Shanmugaraj">Balamurugan Shanmugaraj</name><affiliation wicri:level="1"><nlm:affiliation>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Siriwattananon, Konlavat" sort="Siriwattananon, Konlavat" uniqKey="Siriwattananon K" first="Konlavat" last="Siriwattananon">Konlavat Siriwattananon</name><affiliation wicri:level="1"><nlm:affiliation>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Wangkanont, Kittikhun" sort="Wangkanont, Kittikhun" uniqKey="Wangkanont K" first="Kittikhun" last="Wangkanont">Kittikhun Wangkanont</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Phoolcharoen, Waranyoo" sort="Phoolcharoen, Waranyoo" uniqKey="Phoolcharoen W" first="Waranyoo" last="Phoolcharoen">Waranyoo Phoolcharoen</name><affiliation wicri:level="1"><nlm:affiliation>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32134278</idno><idno type="pmid">32134278</idno><idno type="doi">10.12932/AP-200220-0773</idno><idno type="wicri:Area/PubMed/Corpus">000807</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000807</idno><idno type="wicri:Area/PubMed/Curation">000807</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000807</idno><idno type="wicri:Area/PubMed/Checkpoint">000467</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000467</idno><idno type="wicri:Area/Ncbi/Merge">000D72</idno><idno type="wicri:Area/Ncbi/Curation">000D72</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D72</idno><idno type="wicri:doubleKey">0125-877X:2020:Shanmugaraj B:perspectives:on:monoclonal</idno><idno type="wicri:Area/Main/Merge">000508</idno><idno type="wicri:Area/Main/Curation">000506</idno><idno type="wicri:Area/Main/Exploration">000506</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).</title><author><name sortKey="Shanmugaraj, Balamurugan" sort="Shanmugaraj, Balamurugan" uniqKey="Shanmugaraj B" first="Balamurugan" last="Shanmugaraj">Balamurugan Shanmugaraj</name><affiliation wicri:level="1"><nlm:affiliation>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Siriwattananon, Konlavat" sort="Siriwattananon, Konlavat" uniqKey="Siriwattananon K" first="Konlavat" last="Siriwattananon">Konlavat Siriwattananon</name><affiliation wicri:level="1"><nlm:affiliation>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Wangkanont, Kittikhun" sort="Wangkanont, Kittikhun" uniqKey="Wangkanont K" first="Kittikhun" last="Wangkanont">Kittikhun Wangkanont</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Phoolcharoen, Waranyoo" sort="Phoolcharoen, Waranyoo" uniqKey="Phoolcharoen W" first="Waranyoo" last="Phoolcharoen">Waranyoo Phoolcharoen</name><affiliation wicri:level="1"><nlm:affiliation>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Research unit for Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author></analytic><series><title level="j">Asian Pacific journal of allergy and immunology</title><idno type="ISSN">0125-877X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Neutralizing (therapeutic use)</term><term>Antibodies, Viral (therapeutic use)</term><term>Betacoronavirus</term><term>Binding Sites</term><term>China</term><term>Coronavirus Infections (therapy)</term><term>Humans</term><term>Immunotherapy</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>Pneumonia, Viral (therapy)</term><term>Protein Structure, Tertiary</term><term>Receptors, Virus (chemistry)</term><term>SARS Virus</term><term>Spike Glycoprotein, Coronavirus (chemistry)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps antiviraux (usage thérapeutique)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps neutralisants (usage thérapeutique)</term><term>Chine</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Glycoprotéine de spicule des coronavirus ()</term><term>Humains</term><term>Immunothérapie</term><term>Infections à coronavirus ()</term><term>Pneumopathie virale ()</term><term>Récepteurs viraux ()</term><term>Sites de fixation</term><term>Structure tertiaire des protéines</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Receptors, Virus</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps monoclonaux</term><term>Anticorps neutralisants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Binding Sites</term><term>Humans</term><term>Immunotherapy</term><term>Middle East Respiratory Syndrome Coronavirus</term><term>Protein Structure, Tertiary</term><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Chine</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term><term>Immunothérapie</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Récepteurs viraux</term><term>Sites de fixation</term><term>Structure tertiaire des protéines</term><term>Virus du SRAS</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République populaire de Chine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently novel coronavirus (2019-nCoV or SARS-CoV-2). The disease condition associated with novel coronavirus, referred to as Coronavirus disease (COVID-19). The emergence of novel coronavirus in 2019 in Wuhan, China marked the third highly pathogenic coronavirus infecting humans in the 21st century. The continuing emergence of coronaviruses at regular intervals poses a significant threat to human health and economy. Ironically, even after a decade of research on coronavirus, still there are no licensed vaccines or therapeutic agents to treat coronavirus infection which highlights an urgent need to develop effective vaccines or post-exposure prophylaxis to prevent future epidemics. Several clinical, genetic and epidemiological features of COVID-19 resemble SARS-CoV infection. Hence, the research advancements on SARS-CoV treatment might help scientific community in quick understanding of this virus pathogenesis and develop effective therapeutic/prophylactic agents to treat and prevent this infection. Monoclonal antibodies represent the major class of biotherapeutics for passive immunotherapy to fight against viral infection. The therapeutic potential of monoclonal antibodies has been well recognized in the treatment of many diseases. Here, we summarize the potential monoclonal antibody based therapeutic intervention for COVID-19 by considering the existing knowledge on the neutralizing monoclonal antibodies against similar coronaviruses SARS-CoV and MERS-CoV. Further research on COVID-19 pathogenesis could identify appropriate therapeutic targets to develop specific anti-virals against this newly emerging pathogen.</div></front></TEI><affiliations><list><country><li>Thaïlande</li></country></list><tree><country name="Thaïlande"><noRegion><name sortKey="Shanmugaraj, Balamurugan" sort="Shanmugaraj, Balamurugan" uniqKey="Shanmugaraj B" first="Balamurugan" last="Shanmugaraj">Balamurugan Shanmugaraj</name></noRegion><name sortKey="Phoolcharoen, Waranyoo" sort="Phoolcharoen, Waranyoo" uniqKey="Phoolcharoen W" first="Waranyoo" last="Phoolcharoen">Waranyoo Phoolcharoen</name><name sortKey="Siriwattananon, Konlavat" sort="Siriwattananon, Konlavat" uniqKey="Siriwattananon K" first="Konlavat" last="Siriwattananon">Konlavat Siriwattananon</name><name sortKey="Wangkanont, Kittikhun" sort="Wangkanont, Kittikhun" uniqKey="Wangkanont K" first="Kittikhun" last="Wangkanont">Kittikhun Wangkanont</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000506 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000506 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32134278
|texte= Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32134278" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |